دورية أكاديمية
أعرض في EDS

Metabolic dialogues: regulators of chimeric antigen receptor T cell function in the tumor microenvironment.

التفاصيل البيبلوغرافية
العنوان: Metabolic dialogues: regulators of chimeric antigen receptor T cell function in the tumor microenvironment.
المؤلفون: Moraly J; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Université Sorbonne Paris Cité, Paris, France., Kondo T; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Benzaoui M; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Université de Montpellier, Institut de Génétique Moléculaire de Montpellier, CNRS, Montpellier, France., DuSold J; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Talluri S; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Pouzolles MC; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Chien C; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Dardalhon V; Université de Montpellier, Institut de Génétique Moléculaire de Montpellier, CNRS, Montpellier, France., Taylor N; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Université de Montpellier, Institut de Génétique Moléculaire de Montpellier, CNRS, Montpellier, France.
المصدر: Molecular oncology [Mol Oncol] 2024 Jul; Vol. 18 (7), pp. 1695-1718. Date of Electronic Publication: 2024 Jun 22.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2017- : Hoboken, New Jersey : John Wiley & Sons, Inc.
Original Publication: Amsterdam : Elsevier
مواضيع طبية MeSH: Tumor Microenvironment*/immunology , Receptors, Chimeric Antigen*/metabolism , Receptors, Chimeric Antigen*/immunology, Humans ; Animals ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Neoplasms/immunology ; Neoplasms/therapy ; Neoplasms/metabolism ; Neoplasms/pathology ; Immunotherapy, Adoptive/methods
مستخلص: Tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T cells have demonstrated remarkable success in the treatment of relapsed/refractory melanoma and hematological malignancies, respectively. These treatments have marked a pivotal shift in cancer management. However, as "living drugs," their effectiveness is dependent on their ability to proliferate and persist in patients. Recent studies indicate that the mechanisms regulating these crucial functions, as well as the T cell's differentiation state, are conditioned by metabolic shifts and the distinct utilization of metabolic pathways. These metabolic shifts, conditioned by nutrient availability as well as cell surface expression of metabolite transporters, are coupled to signaling pathways and the epigenetic landscape of the cell, modulating transcriptional, translational, and post-translational profiles. In this review, we discuss the processes underlying the metabolic remodeling of activated T cells, the impact of a tumor metabolic environment on T cell function, and potential metabolic-based strategies to enhance T cell immunotherapy.
(© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.)
References: Cell Metab. 2022 Apr 5;34(4):516-532.e11. (PMID: 35316657)
J Transl Med. 2016 Jul 19;14(1):214. (PMID: 27435312)
J Clin Invest. 2021 Feb 15;131(4):. (PMID: 33320840)
Cell. 2015 Sep 10;162(6):1229-41. (PMID: 26321679)
Blood. 2007 Feb 1;109(3):1034-42. (PMID: 17023582)
Nat Med. 2015 Jun;21(6):581-90. (PMID: 25939063)
Viruses. 2023 Jan 18;15(2):. (PMID: 36851488)
Cell. 2011 Sep 2;146(5):772-84. (PMID: 21871655)
Nat Immunol. 2016 Jan;17(1):104-12. (PMID: 26551880)
Trends Immunol. 2023 Mar;44(3):231-244. (PMID: 36774330)
Immunity. 2021 Apr 13;54(4):829-844.e5. (PMID: 33705706)
Nat Genet. 2023 Dec;55(12):2211-2223. (PMID: 37945901)
Cell. 2021 Aug 5;184(16):4186-4202.e20. (PMID: 34216540)
Semin Immunol. 2016 Oct;28(5):514-524. (PMID: 27825556)
Cell Rep. 2023 Sep 26;42(9):113013. (PMID: 37632752)
Sci Transl Med. 2022 Nov 9;14(670):eabo4997. (PMID: 36350991)
Cancer Res. 2006 Nov 15;66(22):10995-1004. (PMID: 17108138)
Cell. 2016 Oct 20;167(3):829-842.e13. (PMID: 27745970)
Science. 2016 Jan 1;351(6268):53-8. (PMID: 26586190)
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7797-802. (PMID: 18509048)
Cancer Res Commun. 2021 Oct 19;1(1):41-55. (PMID: 36860911)
Blood. 2019 Jul 4;134(1):44-58. (PMID: 31076448)
Nature. 2021 Mar;591(7851):652-658. (PMID: 33588426)
Nat Microbiol. 2016 Jun 24;1(7):16105. (PMID: 27572983)
Nature. 2023 Sep;621(7980):849-856. (PMID: 37730993)
Nat Commun. 2017 May 22;8:15338. (PMID: 28530241)
Cell Res. 2020 Aug;30(8):649-659. (PMID: 32709897)
Nature. 2021 Mar;591(7851):645-651. (PMID: 33589820)
J Clin Invest. 2015 Jan;125(1):194-207. (PMID: 25437876)
PLoS Biol. 2004 Aug;2(8):E243. (PMID: 15314659)
Nature. 2023 Mar;615(7951):315-322. (PMID: 36755094)
Front Immunol. 2022 Mar 31;13:843242. (PMID: 35432304)
Nat Med. 2014 Nov;20(11):1327-33. (PMID: 25282359)
Nat Commun. 2015 Mar 26;6:6692. (PMID: 25809635)
J Immunol. 2013 Jun 15;190(12):6043-50. (PMID: 23690474)
Immunity. 2023 Sep 12;56(9):2036-2053.e12. (PMID: 37572656)
Nat Rev Endocrinol. 2022 Jan;18(1):7-8. (PMID: 34824384)
Front Immunol. 2018 Jul 27;9:1740. (PMID: 30140266)
Nat Commun. 2017 May 10;8:15207. (PMID: 28488695)
N Engl J Med. 2014 Oct 16;371(16):1507-17. (PMID: 25317870)
Lancet. 2015 Feb 7;385(9967):517-528. (PMID: 25319501)
Nat Immunol. 2023 Feb;24(2):267-279. (PMID: 36543958)
Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):6047-6055. (PMID: 32123114)
Trends Cell Biol. 2021 Jan;31(1):24-36. (PMID: 33092942)
Nat Cancer. 2023 Oct;4(10):1508-1525. (PMID: 37723306)
Cell. 2018 Dec 13;175(7):1780-1795.e19. (PMID: 30392958)
J Clin Invest. 2013 Feb;123(2):594-9. (PMID: 23281401)
Int J Cancer. 2019 Sep 1;145(5):1312-1324. (PMID: 30737788)
Nat Rev Cancer. 2021 Oct;21(10):669-680. (PMID: 34272515)
Blood. 2008 Feb 15;111(4):2101-11. (PMID: 18042802)
Cell Metab. 2019 Aug 6;30(2):352-363.e8. (PMID: 31130465)
Oncotarget. 2018 Feb 7;9(17):13125-13138. (PMID: 29568345)
Nature. 2017 Aug 10;548(7666):228-233. (PMID: 28783731)
J Immunol. 2004 Dec 15;173(12):7200-8. (PMID: 15585841)
Biomaterials. 2023 Apr;295:122052. (PMID: 36827893)
Immunity. 2012 Jan 27;36(1):68-78. (PMID: 22206904)
Nat Commun. 2019 Jul 5;10(1):3000. (PMID: 31278254)
Cancer Cell. 2018 Mar 12;33(3):480-494.e7. (PMID: 29533786)
Cancer Cell. 2022 Nov 14;40(11):1407-1422.e7. (PMID: 36240777)
Virology. 2004 Jan 5;318(1):183-91. (PMID: 14972546)
Immunol Rev. 2020 May;295(1):5-14. (PMID: 32320073)
Cell Host Microbe. 2016 May 11;19(5):713-9. (PMID: 27107939)
Immunity. 2008 Dec 19;29(6):848-62. (PMID: 19100699)
Cells. 2021 Dec 08;10(12):. (PMID: 34943965)
Nat Immunol. 2013 May;14(5):500-8. (PMID: 23525088)
Nat Immunol. 2020 Nov;21(11):1397-1407. (PMID: 32989328)
JCI Insight. 2019 Mar 7;4(5):. (PMID: 30721155)
Science. 2019 Mar 29;363(6434):. (PMID: 30923193)
J Exp Med. 2010 Jul 5;207(7):1347-50. (PMID: 20603315)
Cancer Res. 2015 Jan 15;75(2):296-305. (PMID: 25432172)
Cell. 2018 Dec 13;175(7):1958-1971.e15. (PMID: 30449619)
EMBO J. 2011 Aug 16;30(19):3895-912. (PMID: 21847095)
Immunity. 2016 Aug 16;45(2):358-73. (PMID: 27496729)
Mol Cell. 2000 Sep;6(3):683-92. (PMID: 11030347)
J Immunol. 2004 Mar 1;172(5):2731-8. (PMID: 14978070)
Curr Opin Biotechnol. 2023 Dec;84:103020. (PMID: 37976958)
Immunity. 2010 Jun 25;32(6):743-53. (PMID: 20620941)
Cancer Discov. 2021 May;11(5):1192-1211. (PMID: 33328215)
Nat Commun. 2022 Sep 6;13(1):4981. (PMID: 36068198)
J Exp Med. 2020 Aug 3;217(8):. (PMID: 32491160)
Cancers (Basel). 2020 Oct 12;12(10):. (PMID: 33053779)
Blood. 2022 Jan 27;139(4):523-537. (PMID: 35084470)
Cancer Immunol Res. 2019 May;7(5):759-772. (PMID: 30890531)
Nature. 2019 Dec;576(7787):471-476. (PMID: 31827283)
J Immunother Cancer. 2023 Jun;11(6):. (PMID: 37399358)
Nat Med. 2009 Jul;15(7):808-13. (PMID: 19525962)
Cell Rep. 2016 Aug 2;16(5):1243-1252. (PMID: 27452473)
Cell Metab. 2017 Jun 6;25(6):1282-1293.e7. (PMID: 28416194)
Blood. 2016 Jul 28;128(4):519-28. (PMID: 27226436)
Cell Mol Immunol. 2022 Mar;19(3):316-326. (PMID: 35039633)
Cell Metab. 2019 Jul 2;30(1):143-156.e5. (PMID: 31031094)
Cell Metab. 2022 May 3;34(5):731-746.e9. (PMID: 35452600)
Nat Rev Immunol. 2016 Mar;16(3):177-92. (PMID: 26922909)
Elife. 2020 Nov 23;9:. (PMID: 33226340)
J Exp Med. 2018 Apr 2;215(4):1091-1100. (PMID: 29511066)
Nat Cell Biol. 2016 Oct;18(10):1090-101. (PMID: 27617932)
Cancers (Basel). 2021 Jul 14;13(14):. (PMID: 34298748)
Science. 2019 Aug 2;365(6452):. (PMID: 31371577)
Cell Metab. 2016 Nov 8;24(5):657-671. (PMID: 27641098)
Nature. 2021 Sep;597(7877):544-548. (PMID: 34526724)
Immunity. 2016 Feb 16;44(2):380-90. (PMID: 26885860)
Immunity. 2013 Feb 21;38(2):225-36. (PMID: 23415911)
Mol Cell. 2020 Nov 19;80(4):592-606.e8. (PMID: 33159855)
J Exp Med. 2011 Jul 4;208(7):1367-76. (PMID: 21708926)
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4194-9. (PMID: 17360499)
Front Immunol. 2018 Dec 13;9:2955. (PMID: 30619315)
Nat Immunol. 2020 Aug;21(8):927-937. (PMID: 32632289)
Clin Cancer Res. 2021 Nov 1;27(21):6026-6038. (PMID: 34233960)
Cell Metab. 2017 Feb 7;25(2):345-357. (PMID: 28111214)
Nat Commun. 2020 Aug 11;11(1):4011. (PMID: 32782249)
Front Immunol. 2019 Nov 26;10:2718. (PMID: 31849941)
Front Pharmacol. 2023 Oct 26;14:1241677. (PMID: 37954858)
Science. 2020 Dec 11;370(6522):1328-1334. (PMID: 33303615)
Cell. 2017 Oct 5;171(2):385-397.e11. (PMID: 28919076)
Sci Immunol. 2019 Jan 25;4(31):. (PMID: 30683669)
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E4051-E4060. (PMID: 29632189)
Science. 2008 Jun 13;320(5882):1496-501. (PMID: 18497260)
J Immunol. 2016 Sep 15;197(6):2532-40. (PMID: 27511728)
Nat Med. 2015 Apr;21(4):327-34. (PMID: 25799228)
Cell Mol Immunol. 2022 Mar;19(3):409-420. (PMID: 35121805)
Nat Immunol. 2021 Feb;22(2):205-215. (PMID: 33398183)
Nat Chem Biol. 2022 May;18(5):470-481. (PMID: 35484263)
Cancer Res. 2020 Feb 1;80(3):471-483. (PMID: 31767627)
Cell Metab. 2021 Nov 2;33(11):2189-2200.e3. (PMID: 34508697)
Cell Metab. 2020 Dec 1;32(6):1063-1075.e7. (PMID: 33264598)
Blood Adv. 2023 May 9;7(9):1754-1761. (PMID: 36521029)
Cell. 2016 Apr 21;165(3):535-50. (PMID: 27104977)
Nat Biomed Eng. 2022 Feb;6(2):118-128. (PMID: 35190680)
EMBO J. 2011 Apr 6;30(7):1238-50. (PMID: 21326213)
Biochem J. 2002 Oct 1;367(Pt 1):121-8. (PMID: 12099890)
Retrovirology. 2007 May 15;4:31. (PMID: 17504522)
Immunity. 2009 Jun 19;30(6):832-44. (PMID: 19538929)
Nat Immunol. 2020 Sep;21(9):1022-1033. (PMID: 32661364)
Nat Immunol. 2011 Apr;12(4):295-303. (PMID: 21358638)
Nat Rev Cancer. 2018 Oct;18(10):601-618. (PMID: 30006588)
Cell. 2015 Sep 10;162(6):1217-28. (PMID: 26321681)
Br J Cancer. 2023 Nov;129(10):1546-1557. (PMID: 37689804)
Nat Immunol. 2020 Dec;21(12):1540-1551. (PMID: 33020660)
JCI Insight. 2018 Sep 20;3(18):. (PMID: 30232281)
Nat Metab. 2020 Oct;2(10):1001-1012. (PMID: 32958939)
Nat Immunol. 2016 Jun;17(6):704-11. (PMID: 27064374)
Immunity. 2019 Nov 19;51(5):856-870.e5. (PMID: 31747582)
Cell Rep. 2023 Mar 28;42(3):112153. (PMID: 36848289)
Nature. 2016 Apr 21;532(7599):389-93. (PMID: 27064903)
Nat Metab. 2019 Jul;1(7):717-730. (PMID: 32373781)
Nat Commun. 2021 Mar 5;12(1):1455. (PMID: 33674593)
Immunity. 2013 Dec 12;39(6):1143-57. (PMID: 24315997)
Nat Immunol. 2021 Aug;22(8):983-995. (PMID: 34282330)
Front Endocrinol (Lausanne). 2019 Jan 21;9:807. (PMID: 30719023)
Nat Rev Clin Oncol. 2019 Jun;16(6):372-385. (PMID: 30837712)
Cell. 2017 Nov 16;171(5):1015-1028.e13. (PMID: 29056339)
Nature. 2001 Dec 20-27;414(6866):916-20. (PMID: 11780065)
Nat Immunol. 2009 Jul;10(7):769-77. (PMID: 19483717)
Immunity. 2019 Jun 18;50(6):1498-1512.e5. (PMID: 31097342)
Cancer Cell. 2023 Mar 13;41(3):421-433. (PMID: 36801000)
Immunity. 2019 Jun 18;50(6):1347-1349. (PMID: 31216458)
Int J Cancer. 2013 Feb 1;132(3):E85-93. (PMID: 22815199)
Oncoimmunology. 2018 Aug 6;7(10):e1488565. (PMID: 30288356)
Cell. 2021 Mar 4;184(5):1245-1261.e21. (PMID: 33636132)
Sci Signal. 2020 Mar 31;13(625):. (PMID: 32234960)
Cancer Res. 2006 Jan 15;66(2):1114-22. (PMID: 16424048)
Cell. 2016 Jun 30;166(1):63-76. (PMID: 27293185)
Cell Metab. 2022 Apr 5;34(4):595-614.e14. (PMID: 35276062)
Blood. 2014 Jun 12;123(24):3750-9. (PMID: 24782509)
Mol Cell. 2020 Nov 19;80(4):555-557. (PMID: 33217313)
Immunity. 2014 May 15;40(5):692-705. (PMID: 24792914)
Nat Med. 2011 Sep 18;17(10):1290-7. (PMID: 21926977)
Cell. 2013 Jun 6;153(6):1239-51. (PMID: 23746840)
Nature. 2020 Sep;585(7824):277-282. (PMID: 32879489)
Immunity. 2018 Mar 20;48(3):542-555.e6. (PMID: 29523440)
Blood. 2020 Sep 3;136(10):1155-1160. (PMID: 32573723)
Cell. 2021 Aug 5;184(16):4168-4185.e21. (PMID: 34216539)
Nat Med. 2018 May;24(5):563-571. (PMID: 29713085)
J Immunol. 2011 Mar 15;186(6):3299-303. (PMID: 21317389)
J Immunol. 2018 Sep 1;201(5):1400-1411. (PMID: 30030325)
Nat Metab. 2020 Aug;2(8):703-716. (PMID: 32747793)
Cell. 2021 Jan 21;184(2):404-421.e16. (PMID: 33357445)
JCI Insight. 2017 Jun 15;2(12):. (PMID: 28614802)
Annu Rev Immunol. 2018 Apr 26;36:461-488. (PMID: 29677474)
Protein Cell. 2019 Oct;10(10):764-769. (PMID: 31250350)
Science. 2017 Nov 10;358(6364):813-818. (PMID: 29123071)
Cell Metab. 2018 Dec 4;28(6):895-906.e5. (PMID: 30197303)
Cell Metab. 2014 Jul 1;20(1):61-72. (PMID: 24930970)
J Immunol. 2016 May 1;196(9):3618-30. (PMID: 27022197)
Mol Cell. 2020 Nov 5;80(3):384-395. (PMID: 32997964)
Nature. 2016 Sep 22;537(7621):539-543. (PMID: 27626381)
Nat Commun. 2023 Dec 13;14(1):8260. (PMID: 38086839)
Nat Metab. 2022 Dec;4(12):1660-1673. (PMID: 36376563)
Nat Commun. 2019 Aug 21;10(1):3763. (PMID: 31434891)
J Immunother Cancer. 2023 Mar;11(3):. (PMID: 36914208)
Cancer Cell. 2015 Oct 12;28(4):415-428. (PMID: 26461090)
J Immunol. 2005 Aug 1;175(3):1483-90. (PMID: 16034085)
Nat Genet. 2002 Apr;30(4):406-10. (PMID: 11865300)
Cell Mol Immunol. 2022 Mar;19(3):303-315. (PMID: 34983947)
Immunometabolism. 2022;4(2):. (PMID: 35371563)
Nature. 2016 Mar 31;531(7596):651-5. (PMID: 26982734)
Cancer Cell. 2022 Feb 14;40(2):201-218.e9. (PMID: 35090594)
PLoS One. 2013;8(2):e55146. (PMID: 23424623)
J Immunol. 2020 May 1;204(9):2575-2588. (PMID: 32221038)
J Clin Invest. 2016 Jan;126(1):318-34. (PMID: 26657860)
Immunity. 2023 Jun 13;56(6):1341-1358.e11. (PMID: 37315536)
JCI Insight. 2017 Dec 7;2(23):. (PMID: 29212954)
Blood. 2023 May 18;141(20):2520-2536. (PMID: 36735910)
J Exp Med. 2018 Jun 4;215(6):1555-1569. (PMID: 29743292)
Immunity. 2017 Mar 21;46(3):488-503. (PMID: 28285833)
J Exp Med. 2002 Aug 19;196(4):447-57. (PMID: 12186837)
Nature. 2016 Apr 28;532(7600):512-6. (PMID: 27096360)
Nat Rev Clin Oncol. 2023 Apr;20(4):211-228. (PMID: 36721024)
Bioelectricity. 2019 Sep 1;1(3):169-179. (PMID: 34471819)
Semin Immunol. 2016 Feb;28(1):64-72. (PMID: 26611350)
Sci Rep. 2016 Apr 12;6:24129. (PMID: 27067254)
Sci Signal. 2015 Sep 29;8(396):ra97. (PMID: 26420908)
Annu Rev Immunol. 2013;31:259-83. (PMID: 23298210)
J Exp Med. 2008 Mar 17;205(3):565-74. (PMID: 18283119)
Nature. 2001 Feb 8;409(6821):733-9. (PMID: 11217864)
Nat Immunol. 2019 Nov;20(11):1542-1554. (PMID: 31591570)
Elife. 2014 Nov 11;3:. (PMID: 25385531)
Leukemia. 2018 May;32(5):1157-1167. (PMID: 29479065)
J Hematol Oncol. 2023 Sep 12;16(1):103. (PMID: 37700339)
Science. 2022 Sep 30;377(6614):1519-1529. (PMID: 36173860)
Nat Commun. 2022 Dec 17;13(1):7796. (PMID: 36528626)
Nature. 2021 May;593(7858):282-288. (PMID: 33828302)
Cell Rep. 2018 Feb 6;22(6):1509-1521. (PMID: 29425506)
Science. 2009 Jun 5;324(5932):1334-8. (PMID: 19498172)
N Engl J Med. 2018 Feb 1;378(5):449-459. (PMID: 29385376)
Immunity. 2016 Aug 16;45(2):374-88. (PMID: 27496732)
J Clin Invest. 2013 Oct;123(10):4479-88. (PMID: 24091329)
Immunity. 2022 Nov 8;55(11):2059-2073.e8. (PMID: 36351375)
Front Endocrinol (Lausanne). 2020 Apr 16;11:191. (PMID: 32425881)
J Exp Med. 2004 Sep 6;200(5):659-69. (PMID: 15353558)
Cell. 2016 Mar 24;165(1):153-164. (PMID: 26972053)
Nat Rev Immunol. 2022 Apr;22(4):209-223. (PMID: 34253904)
FEBS Lett. 2017 Oct;591(19):3104-3118. (PMID: 28901530)
Dev Cell. 2019 Aug 5;50(3):381-392.e5. (PMID: 31257175)
Nat Biotechnol. 2021 Feb;39(2):186-197. (PMID: 32868913)
Mol Cells. 2013 Jun;35(6):463-73. (PMID: 23694989)
Annu Rev Immunol. 2012;30:39-68. (PMID: 22136167)
Nat Cell Biol. 2021 Jan;23(1):75-86. (PMID: 33420490)
Immunol Rev. 2016 Nov;274(1):16-32. (PMID: 27782335)
Pan Afr Med J. 2017 Jun 30;27:163. (PMID: 28904691)
Immunity. 2011 Dec 23;35(6):871-82. (PMID: 22195744)
Cell Rep. 2015 Nov 10;13(6):1118-1124. (PMID: 26527008)
Nat Rev Clin Oncol. 2024 Jan;21(1):47-66. (PMID: 37904019)
Front Immunol. 2017 Mar 09;8:247. (PMID: 28337199)
Nat Med. 2003 Oct;9(10):1269-74. (PMID: 14502282)
PLoS Biol. 2004 Aug;2(8):E241. (PMID: 15314657)
Cell Metab. 2023 Jun 6;35(6):961-978.e10. (PMID: 37178684)
Cell Rep. 2021 Nov 2;37(5):109911. (PMID: 34731632)
Front Immunol. 2020 May 15;11:938. (PMID: 32499785)
معلومات مُعتمدة: ZIA BC011923 United States ImNIH Intramural NIH HHS; ZIA BC 011923 United States CL CLC NIH HHS; Agence Nationale de la Recherche; ZIA BC 011924 United States CL CLC NIH HHS; ZIA BC011924 United States ImNIH Intramural NIH HHS
فهرسة مساهمة: Keywords: T cells; anti‐tumor immunotherapy; chimeric antigen receptor; immunometabolism; nutrient transporters; tumor microenvironment
المشرفين على المادة: 0 (Receptors, Chimeric Antigen)
تواريخ الأحداث: Date Created: 20240626 Date Completed: 20240704 Latest Revision: 20240706
رمز التحديث: 20240706
مُعرف محوري في PubMed: PMC11223614
DOI: 10.1002/1878-0261.13691
PMID: 38922759
قاعدة البيانات: MEDLINE
الوصف
تدمد:1878-0261
DOI:10.1002/1878-0261.13691